Logo image
Back
In-house manufacture of plasma-derived human AB serum for use in cellular therapeutics
Journal article   Peer reviewed

In-house manufacture of plasma-derived human AB serum for use in cellular therapeutics

Paige O. Mirsky, John Lister and Albert D. Donnenberg
Cytotherapy (Oxford, England), v 28(7), 102117
01 Jul 2026
DOI: https://doi.org/10.1016/j.jcyt.2026.102117
PMID: 42139909
Featured in Collection :   Drexel's Newest Publications

Abstract

cellular therapy cGMP chimeric antigen receptor T cells defibrination human AB serum human plasma tumor infiltrating lymphocytes
Successful manufacture of cellular therapeutic products requires a medium containing key nutrients to support cell expansion. Some of the most common supplements to cell culture media include serum products such as fetal bovine serum, human serum albumin, and human AB serum. Medium supplementation with human AB serum provides critical growth factors, lipids, proteins, and hormones without the risk of cross-species antigenicity or anti-AB antibodies. In this report, we describe the use of pooled defibrinated plasma, sourced from a US blood bank, to produce serum in-house that complies with blood product, cell therapy, and current Good Manufacturing Practice (cGMP) regulations. We are currently using this product as a culture supplement for the in-house manufacture of chimeric antigen receptor T cell (CAR-T) and tumor-infiltrating lymphocyte (TIL) therapeutics under IND. Our current validated clinical laboratory procedure is included as supplementary material.

Metrics

1 Record Views

Details

Logo image